Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics Inc.

Esperion ( ($ESPR) ) has shared an update. On April 2, 2026, Esperion Therapeutics amended its existing credit agreement to add a $25 million term ...

Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR). Passage B...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Passage Bio (PASG), Phreesia (PHR) and Esperion (ESPR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (ESPR – Research Report) and NovaBridge Bio...

Analysts’ Top Healthcare Picks: Esperion (ESPR), NovaBridge Biosciences (NBP)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Esperion today and set a price target of $9.00. According to TipRanks, Amsellem is ...

Current Quarter	$-0.04	Next Quarter	$-0.02
Current Year	$0.05	Next Year	$0.22
QoQ Growth	+50.0%	YoY Growth	+340.0%
3Y EPS CAGR	+68.9%	Target Price	$6.97
Consensus	Buy	Upside	+219.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ESPR	$2.18	0.00%	8.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ESPR	$2.18	0%	8.20M
3
4
5
6

ESPR

ESPR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Esperion Therapeutics Inc. Data in Excel

Get Esperion Therapeutics Inc. Data in Excel